Furen Medicines Group Co., Ltd.

Main objective: To study the pharmacokinetics of the test preparation ibuprofen sustained-release capsules (specification: 0.3g, licensed by Furen Pharmaceutical Group Co., Ltd.) and the reference preparation ibuprofen sustained-release capsules (trade name: Fenbid®, specification: 0.3g, licensed by Sino-US Tianjin SmithKline Pharmaceutical Co., Ltd.) taken orally in healthy adult subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations taken orally under fasting and fed conditions.

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of Cephalexin Capsules (test preparation, 125 mg/capsule) produced by Furen Pharmaceutical Group Co., Ltd. and Cephalexin Capsules (reference preparation, Sencephalin®, 125 mg/capsule) produced by Takeda Pharmaceutical Co., Ltd., to conduct a single dose (250 mg) bioequivalence study in humans under fasting and postprandial conditions, and to conduct a post-marketing drug consistency evaluation. Secondary objective: To observe the safety of the test preparation and the reference preparation after administration in healthy subjects.

Primary objective: To investigate the bioequivalence of domperidone tablets (test preparation, 10 mg/tablet) produced by Furen Pharmaceutical Group Co., Ltd. and Motilium (reference preparation, 10 mg/tablet) produced by Janssen-Cilag, France, after single administration on an empty stomach or after a meal in healthy Chinese subjects. Secondary objective: To observe the safety after administration.